MetaVia Inc. SEC filings MTVA
MetaVia Inc. has 633 filings in SEC EDGAR's recent list, going back to Apr 8, 2015. Its latest annual report, Form ARS, was filed on Apr 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Apr 6, 2026 | — |
| EFFECT | Filing | Jan 15, 2026 | — |
| CORRESP | Letter to the SEC | Jan 14, 2026 | — |
| CORRESP | Letter to the SEC | Jan 14, 2026 | — |
| CORRESP | Letter to the SEC | Jan 7, 2026 | — |
| CORRESP | Letter to the SEC | Jan 7, 2026 | — |
| CORRESP | Letter to the SEC | Jan 5, 2026 | — |
| CORRESP | Letter to the SEC | Jan 5, 2026 | — |
| DRS | Filing | Oct 17, 2025 | — |
| EFFECT | Filing | Jul 10, 2025 | — |
| CORRESP | Letter to the SEC | Jul 8, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 8, 2025 | — |
| D | Filing | May 15, 2025 | — |
| UPLOAD | Letter from the SEC | May 6, 2025 | — |
| CORRESP | Letter to the SEC | May 2, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 28, 2025 | — |
| EFFECT | Filing | Apr 3, 2025 | — |
| EFFECT | Filing | Jul 24, 2024 | — |
| CORRESP | Letter to the SEC | Jul 22, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 22, 2024 | — |
| D | Filing | Jul 1, 2024 | — |
| EFFECT | Filing | Apr 23, 2024 | — |
| CORRESP | Letter to the SEC | Apr 19, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 17, 2024 | — |
| EFFECT | Filing | Jan 31, 2023 | — |
| CORRESP | Letter to the SEC | Jan 27, 2023 | — |
| UPLOAD | Letter from the SEC | Jan 25, 2023 | — |
| EFFECT | Filing | Nov 4, 2022 | — |
| CORRESP | Letter to the SEC | Nov 3, 2022 | — |
| CORRESP | Letter to the SEC | Nov 3, 2022 | — |
| UPLOAD | Letter from the SEC | Sep 22, 2022 | — |
| D | Filing | Oct 18, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 25, 2021 | — |
| CORRESP | Letter to the SEC | Jun 10, 2021 | — |
| PRER14A | Filing | Jun 10, 2021 | — |
| EFFECT | Filing | May 26, 2021 | — |
| CORRESP | Letter to the SEC | May 24, 2021 | — |
| UPLOAD | Letter from the SEC | May 21, 2021 | — |
| EFFECT | Filing | Apr 30, 2021 | — |
| CORRESP | Letter to the SEC | Apr 28, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 26, 2021 | — |
| NT 10-K | Filing | Mar 31, 2021 | Dec 31, 2020 |
| UPLOAD | Letter from the SEC | Mar 23, 2021 | — |
| PRER14A | Pre 14a | Mar 2, 2021 | — |
| CORRESP | Letter to the SEC | Mar 2, 2021 | — |
| UPLOAD | Letter from the SEC | Feb 18, 2021 | — |
| D | Filing | Feb 1, 2021 | — |
| EFFECT | Filing | Jan 29, 2021 | — |
| CORRESP | Letter to the SEC | Jan 27, 2021 | — |
| UPLOAD | Letter from the SEC | Jan 27, 2021 | — |
| D | Filing | Jan 12, 2021 | — |
| NT 10-Q | Filing | May 18, 2020 | Mar 31, 2020 |
| 425 | 8-k | Dec 30, 2019 | — |
| 425 | 8-k | Dec 6, 2019 | — |
| EFFECT | Filing | Nov 6, 2019 | — |
| CORRESP | Letter to the SEC | Nov 4, 2019 | — |
| SEC STAFF LETTER | Filing | Oct 30, 2019 | — |
| 425 | 8-k | Oct 29, 2019 | — |
| CORRESP | Letter to the SEC | Oct 29, 2019 | — |
| UPLOAD | Letter from the SEC | Oct 28, 2019 | — |
| 425 | 8-k | Oct 8, 2019 | — |
| 425 | 8-k | Oct 3, 2019 | — |
| UPLOAD | Letter from the SEC | Oct 3, 2019 | — |
| SEC STAFF LETTER | Filing | Oct 2, 2019 | — |
| 425 | 8-k | Sep 24, 2019 | — |
| 425 | 8-k | Aug 15, 2019 | — |
| 425 | 8-k/a | Aug 13, 2019 | — |
| 425 | 8-k | Aug 9, 2019 | — |
| 425 | 8-k | Jul 25, 2019 | — |
| 425 | Filing | Jul 24, 2019 | — |
| UPLOAD | Letter from the SEC | Aug 28, 2018 | — |
| CT ORDER | Filing | Aug 28, 2018 | — |
| CORRESP | Letter to the SEC | Aug 22, 2018 | — |
| UPLOAD | Letter from the SEC | Aug 14, 2018 | — |
| EFFECT | Filing | Sep 12, 2017 | — |
| EFFECT | Filing | Sep 8, 2017 | — |
| CORRESP | Letter to the SEC | Sep 8, 2017 | — |
| UPLOAD | Letter from the SEC | Sep 7, 2017 | — |
| EFFECT | Filing | Apr 20, 2017 | — |
| CORRESP | Letter to the SEC | Apr 19, 2017 | — |
| UPLOAD | Letter from the SEC | Apr 18, 2017 | — |
| D | Filing | Mar 30, 2017 | — |
| CT ORDER | Filing | Aug 5, 2016 | — |
| EFFECT | Filing | Aug 4, 2016 | — |
| CORRESP | Letter to the SEC | Aug 4, 2016 | — |
| CORRESP | Letter to the SEC | Aug 4, 2016 | — |
| CORRESP | Letter to the SEC | Jul 8, 2016 | — |
| CORRESP | Letter to the SEC | Jul 8, 2016 | — |
| CERTNAS | Auto-generated paper document | Jun 21, 2016 | — |
| 8-A12B | Filing | Jun 20, 2016 | — |
| CORRESP | Letter to the SEC | Jun 20, 2016 | — |
| CORRESP | Letter to the SEC | Jun 20, 2016 | — |
| CORRESP | Letter to the SEC | Jun 15, 2016 | — |
| CORRESP | Letter to the SEC | May 3, 2016 | — |
| UPLOAD | Letter from the SEC | May 2, 2016 | — |
| D/A | Filing | Apr 27, 2016 | — |
| CORRESP | Letter to the SEC | Apr 22, 2016 | — |
| D/A | Filing | Mar 10, 2016 | — |
| DRSLTR | Filing | Jan 19, 2016 | — |
| DRS/A | Filing | Jan 19, 2016 | — |
| D/A | Filing | Dec 22, 2015 | — |
| UPLOAD | Letter from the SEC | Oct 7, 2015 | — |
| DRSLTR | Filing | Sep 11, 2015 | — |
| DRS | Filing | Sep 11, 2015 | — |
| D/A | Filing | Aug 7, 2015 | — |
| D | Filing | Aug 7, 2015 | — |
| D | Filing | Apr 15, 2015 | — |
| D | Filing | Apr 8, 2015 | — |
Showing 108 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MTVA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1638287
- Former names
- NeuroBo Pharmaceuticals, Inc. (until Nov 18, 2024); Gemphire Therapeutics Inc. (until Dec 31, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.